Organisation paid for research Program year 2025 Source: CMS Open Payments

Paul W Wallace

Neither a doctor nor a teaching hospital

Research payments

$1,263,674

112 payments

Through program year 2025, Paul W Wallace is reported as receiving $1,263,674 in research payments, across 112 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$15,201	3
2024	Research	$69,075	12
2023	Research	$83,780	11
2022	Research	$114,262	11
2021	Research	$236,877	23
2020	Research	$382,693	32
2019	Research	$361,787	20

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,263,674 112 payments

Studies the money was for Research payments · program years 2019–2025

M18-891 $476,897 22 payments
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $233,833 33 payments
M15-997 $215,174 13 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $152,101 11 payments
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $66,783 7 payments
M15-999 $37,721 10 payments
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) $25,683 2 payments
M16-833 $14,689 7 payments
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $11,426 1 payment
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $11,376 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.